Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2

American Journal of Pathology

Volumn 174, Issue 1, 2009, Pages 136-143

  Lin, Zhenhua ^a,c,d   Yemelyanova, Anna V ^a   Gambhira, Ratish ^a   Jagu, Subhashini ^a   Meyers, Craig ^e   Kirnbauer, Reinhard ^f   Ronnett, Brigitte M ^a   Gravitt, Patti E ^a,b   Roden, Richard B S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c YANBIAN UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; DAXX PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RG 1; PROMYELOCYTIC LEUKEMIA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONDYLOMA; CONTROLLED STUDY; GENE CONSTRUCT; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SQUAMOUS CELL CARCINOMA; TISSUE CULTURE CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; VIRUS GENOME; WART VIRUS;

EID: 58249119452     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080588     Document Type: Article

References (42)

1. Firzlaff JM, Kiviat NB, Beckmann AM, Jenison SA, Galloway DA: Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology 1988, 164:467-477
2. Auvinen E, Kujari H, Arstila P, Hukkanen V: Expression of the L2 and E7 genes of the human papillomavirus type 16 in female genital dysplasias. Am J Pathol 1992, 141:1217-1224
3. Crum CP, Barber S, Symbula M, Snyder K, Saleh AM, Roche JK: Coexpression of the human papillomavirus type 16 E4 and L1 open reading frames in early cervical neoplasia. Virology 1990, 178:238-246
4. Lacey CJ, Wells M, Macdermott RI, Gibson PE: Human papillomavirus type 16 infection of the cervix: a comparison of differing DNA detection modes and the use of monoclonal antibodies against the major capsid protein. Genitourin Med 1991, 67:87-91
5. Schwartz S: Regulation of human papillomavirus late gene expression. Ups J Med Sci 2000, 105:171-192
6. Bieniasz PD: Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004, 5:1109-1115
7. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T: Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 2006, 80:8006-8018
8. Tavalai N, Papior P, Rechter S, Stamminger T: Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J Virol 2008, 82:126-137
9. Day PM, Roden RB, Lowy DR, Schiller JT: The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 1998, 72:142-150
10. Florin L, Sapp C, Streeck RE, Sapp M: Assembly and translocation of papillomavirus capsid proteins. J Virol 2002, 76:10009-10014
11. Kieback E, Muller M: Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. Virology 2006, 345:199-208
12. Nakahara T, Lambert PF: Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology 2007, 366:316-329
13. Becker KA, Florin L, Sapp C, Maul GG, Sapp M: Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol 2004, 78:1121-1128
14. Florin L, Schafer F, Sotlar K, Streeck RE, Sapp M: Reorganization of nuclear domain 10 induced by papillomavirus capsid protein l2. Virology 2002, 295:97-107
15. Florin L, Becker KA, Sapp C, Lambert C, Sirma H, Muller M, Streeck RE, Sapp M: Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J Virol 2004, 78:5546-5553
16. Görnemann J, Hofmann TG, Will H, Muller M: Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins. Virology 2002, 303:69-78
17. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB: A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007, 81:13927-13931
18. Meyers C, Frattini MG, Hudson JB, Laimins LA: Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992, 257:971-973
19. McLaughlin-Drubin ME, Christensen ND, Meyers C: Propagation, infection, and neutralization of authentic HPV16 virus. Virology 2004, 322:213-219
20. Meyers C, Mayer TJ, Ozbun MA: Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 1997, 71:7381-7386
21. Everett RD, Maul GG: HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J 1994, 13:5062-5069
22. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG: Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 1996, 10:196-207
23. Maul GG, Yu E, Ishov AM, Epstein AL: Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J Cell Biochem 1995, 59:498-513
24. Embers ME, Budgeon LR, Pickel M, Christensen ND: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of l2, the minor capsid protein. J Virol 2002, 76:9798-9805
25. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB: Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2. J Virol 2007, 81:13927-13931
26. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH: Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004, 10:2954-2961
27. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ: Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005, 192:2099-2107
28. Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC: Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006, 16:1075-1081
29. Jarrett WF, Smith KT, O'Neil BW, Gaukroger JM, Chandrachud LM, Grindlay GJ, McGarvie GM, Campo MS: Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991, 184:33-42
30. Ishov AM, Maul GG: The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J Cell Biol 1996, 134:815-826
31. Maul GG, Ishov AM, Everett RD: Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1. Virology 1996, 217:67-75
32. Ishov AM, Stenberg RM, Maul GG: Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J Cell Biol 1997, 138:5-16
33. Tang Q, Bell P, Tegtmeyer P, Maul GG: Replication but not transcription of simian virus 40 DNA is dependent on nuclear domain 10. J Virol 2000, 74:9694-9700
34. Jul-Larsen A, Visted T, Karlsen BO, Rinaldo CH, Bjerkvig R, Lonning PE, Boe SO: PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Exp Cell Res 2004, 298:58-73
35. Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT: Human papillomavirus DNA replication compartments in a transient DNA replication system. J Virol 1999, 73:1001-1009
36. Day PM, Baker CC, Lowy DR, Schiller JT: Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci USA 2004, 101:14252-14257
37. Sato S, Chiba H, Shikano K, Horiguchi M, Wada Y, Yajima A, Okagaki T: Ultrastructural observation of human papillomavirus particles in the uterine cervix intraepithelial neoplasia. Gan No Rinsho 1988, 34:993-1000
38. Stoler MH, Schiffman M: Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505
39. Cai B, Ronnett BM, Stoler M, Ferenczy A, Kurman RJ, Sadow D, Alvarez F, Pearson J, Sings HL, Barr E, Liaw KL: Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists. Am J Surg Pathol 2007, 31:1854-1860
40. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, El-Sherif A, Morris L, Seth R, Hibma M, Jenkins D, Lambert P, Coleman N, Doorbar J: Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003, 77:10186-10201
41. Bauer HM, Greer CE, Manos MM: Determination of Genital Human Papillomavirus Infection by Consensus PCR Amplification. Edited by Herrington CS, McGee JOD. Oxford, Oxford University Press, 1992, pp 131-152
42. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV: Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003, 112:23-33